Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Topical Drugs CDMO Market

Topical Drugs CDMO Market Share

Report ID: GMI9137
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Topical Drugs CDMO Market Share

The market is marked by a highly competitive landscape, characterized by rapid innovation and technological progress. Prominent pharmaceutical and biotechnology companies hold a significant share of the market, driven by their extensive portfolios of topical drugs and advanced treatment options for skin diseases. Strategic initiatives, such as mergers, acquisitions, and collaborations, further strengthen the market position of key players, allowing them to expand their product and services offerings and access new markets.

Topical Drugs CDMO Market Companies

Prominent players operating in the topical drugs CDMO industry include:

Ascendia Pharmaceuticals
Bora Pharmaceuticals
Cambrex
Contract Pharmaceuticals
DPT Laboratories
MedPharm
PCI Pharma Services
Pierre Fabre Group
Piramal Pharma Solutions
The Lubrizol

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global topical drugs CDMO industry was valued at USD 43.7 billion in 2023 and is estimated to grow at a CAGR of over 10.5% from 2024 to 2032, driven by an increasing focus on non-invasive drug delivery systems.

The semi-solid segment accounted for USD 27.3 billion in 2023, with formulations such as creams, ointments, and gels gaining prominence due to their effectiveness in treating various skin conditions.

U.S. topical drugs CDMO industry is expected to grow at a 10.1% CAGR, reaching USD 35 billion by 2032, supported by the presence of leading CDMOs that enhance the production of high-quality topical products.

Key players in the industry include Ascendia Pharmaceuticals, Bora Pharmaceuticals, Cambrex, Contract Pharmaceuticals, DPT Laboratories, MedPharm, PCI Pharma Services, Pierre Fabre Group, Piramal Pharma Solutions, and The Lubrizol.